Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00736190 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection
A Phase 4 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT00736190 is a Phase 4 study that has completed, run by Gilead Sciences. The registered enrollment target is 90 participants.
The verdict
NCT00736190, a Phase 4 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the antiviral activity and safety of tenofovir disoproxil fumarate (TDF) in Asian-American adults (self-reported Asian descent, living in the United States) with chronic hepatitis B infection. All participants will receive active treatment with TDF for 48 weeks.
Interventions
- DRUG Tenofovir disoproxil fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00736190
The ClinicalTrials.gov registry entry for NCT00736190 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tenofovir disoproxil fumarate is the first listed.
NCT00736190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00736190 about?
NCT00736190 is a clinical study titled "A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection". The purpose of this study is to evaluate the antiviral activity and safety of tenofovir disoproxil fumarate (TDF) in Asian-American adults (self-reported Asian descent, living in the United States) with chronic hepatitis B infection. All participants will receive active treatment with TDF for 48 wee...
What is the current status of trial NCT00736190?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2008-08. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00736190?
The interventions under investigation include: Tenofovir disoproxil fumarate (DRUG).
Who is sponsoring clinical trial NCT00736190?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.